Early trial tests adding immunotherapy to standard lung cancer care
NCT ID NCT02621398
Summary
This early-stage study tested the safety of adding a newer immunotherapy drug (pembrolizumab) to the standard treatment of chemotherapy and radiation for patients with inoperable, locally advanced non-small cell lung cancer. The main goal was to find the safest dose and understand the side effects of this combined approach. Researchers hoped the combination would kill more cancer cells and improve outcomes for these patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIA NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.